Related Experiment Videos
Abstract:
Cis-diamminedichloroplatinum has been proven to be an effective neoplastic agent. Nephrotoxicity and ototoxicity are two prominent side effects of this drug. Investigation of ototoxicity has been limited to auditory function. This report details the first known case of vestibular toxicity following platinum therapy. In addition, a prospective vestibular testing program is reported.
Insights
Cisplatin chemotherapy can cause hearing loss. This study reports the first case of cisplatin-induced vestibular toxicity and introduces a new testing program for platinum-based drug side effects.
Area of Science:
- Oncology
- Ototoxicology
- Neuroscience
Background:
- Cis-diamminedichloroplatinum (cisplatin) is a widely used chemotherapeutic agent.
- Nephrotoxicity and ototoxicity are known adverse effects of cisplatin therapy.
- Previous research on cisplatin's ototoxicity has primarily focused on auditory function.
Observation:
- This report documents the first known instance of vestibular toxicity in a patient undergoing platinum-based therapy.
- The patient experienced symptoms indicative of vestibular dysfunction following cisplatin treatment.
Findings:
- The study confirms vestibular toxicity as a potential side effect of cisplatin.
- A prospective vestibular testing program was implemented to systematically evaluate this toxicity.
Implications:
- This research highlights the need to consider vestibular function when monitoring patients on cisplatin.
- The developed testing program may aid in early detection and management of platinum-induced vestibular damage.
- Further investigation is warranted to understand the mechanisms and prevalence of cisplatin-induced vestibular toxicity.